一種檢測血液中鉛含量的系統設計用于兒科醫生、家庭開業者、公共健康保健系統和軍隊診所。該檢測項目將在7月25-27日芝加哥(Il, USA)舉行的美國臨床生化年會(AACC)臨床檢驗博覽會上投放市場。

ESA生物科學公司(Chelmsford, MA, USA)是Magellan生物科學公司的分支機構，將LeadCare II引入該公司獲得了CLIA(臨床實驗室改善管理)豁免資格。LeadCare II是ESA公司原來LeadCare系統的改進版。豁免資格將會擴大擴大那些潛在的結構，從而使得這些機構能夠檢測血鉛:例如在醫生辦公室、社區保健中心、WIC(婦女、嬰兒和兒童)工程和流動診所、保健系統、或者家庭訪問，從而為健康保健系統提供了對最可能面臨鉛中毒危險的兒童和成人進行檢測的新工具。

New System for Detecting Lead in Blood
 
A new system for testing lead in blood is designed for use by pediatricians, family practitioners, public health systems, and military clinics. The test is to be launched at the Clinical Lab Expo at the annual meeting of the American Association for Clinical Chemistry (AACC), July 25-27, in Chicago (Il, USA).

ESA Biosciences Inc. (Chelmsford, MA, USA), a subsidiary of Magellan Biosciences, will introduce LeadCare II providing the company receives CLIA (Clinical Laboratory Improvement Management)-waiver status. LeadCare II is an improved version of ESA’s original LeadCare system. Waived status will expand the potential sites where lead testing can be performed: for example, in physician’s offices, community health centers, WIC (women, infant, and children) programs, and mobile clinics, health fairs, or home visits, thereby giving healthcare providers a new tool to reach those children and adults most at risk for lead poisoning.